Join to view full profile
94 Old Short Hills RdLivingston, NJ 07039
Phone+1 973-322-5200
Fax+1 973-322-8092
Dr. Gallinson is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Medical College at St Vincent's Hospital and Medical Center of New YorkFellowship, Hematology and Medical Oncology, 2001 - 2004
Atlantic HealthResidency, Internal Medicine, 1998 - 2001
Rowan University School of Osteopathic MedicineClass of 1998
Certifications & Licensure
FL State License 2022 - Present
NJ State License 2004 - 2027
PA State License 2012 - 2021
NY State License 2001 - 2004
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012-2014, 2016-2017
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Publications & Presentations
PubMed
- 6 citationsSafety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens
Haematologica. 2025-03-01 - 13 citationsAcalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.Michael Wang, Tadeusz Robak, Kami J Maddocks, Tycel Phillips, Stephen D Smith
Blood Advances. 2024-09-10 - 1082 citationsPemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyGhassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi
The Lancet. Oncology. 2020-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
